This is an exploratory, translational, non-interventional and multi-centre biobank. The aim of the development of such a biobank is to identify potential biomarkers that are indicative of disease relapse.
The primary objective is to develop a biobank, tissue microarrays (TMAs) and full face sections, which will be used to identify candidate/ novel biomarkers prognostic for disease relapse and predictive for endocrine and/or chemotherapy resistance. The secondary objectives are: * To validate emerging signatures/biomarkers identified. * To develop new assays for the breast cancer clinic.
Study Type
OBSERVATIONAL
Enrollment
600
Bons Secours Hospital
Cork, Ireland
Cork University Hospital
Cork, Ireland
Letterkenny General Hospital
Donegal, Ireland
Adelaide and Meath National Children's Hospital Tallaght
Disease relapse, endocrine and/or chemotherapy resistance prognosis
A biobank, TMAs and full face sections, will allow for the identification of candidate/novel biomarkers prognostic for disease relapse and predictive for endocrine and/or chemotherapy resistance
Time frame: For duration of follow up, expected 10 years
Signature/biomarkers
Validation of emerging signature/biomarkers
Time frame: For the duration of follow up, expected 10 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Dublin, Ireland
St Vincent Universtiy Hospital
Dublin, Ireland
St James Hospital
Dublin, Ireland
Beaumont Hospital
Dublin, Ireland
Mater Misericordiae University Hospital
Dublin, Ireland
Galway University Hospital
Galway, Ireland
Midwestern Regional Hospital
Limerick, Ireland
...and 2 more locations